Health
Phase 1 clinical trial shows promising results for monoclonal antibodies against MERS coronavirus – News-Medical.Net
A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory…
A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory syndrome (MERS) found that they were well tolerated and generally safe when administered simultaneously to healthy adults.
The experimental mAbs, REGN3048 and REGN3051, target the MERS coronavirus (MERS CoV) spike protein used by the virus to attach to and infect target cells. The mAbs were discovered and developed by scientists at the biopharmaceutical…
-
Noosa News24 hours agoMeasles alert issued across popular south-east attractions
-
Noosa News22 hours agoBrisbane’s covert cameras catching more than just litterbugs
-
General24 hours agoSector warns Coalition’s plan to limit overseas students ‘straight out of Trump’s playbook’
-
General23 hours agoDonald Trump and the ghost of Al Capone • Inside Story